Peptides

An investigational triple agonist (GLP-1, GIP, and glucagon receptors) studied for obesity and metabolic disease. Currently the highest-profile name in the space—widely framed as the next-generation successor to tirzepatide, with heavy search interest among fitness audiences.

Fat loss · Metabolic

A GLP-1 receptor agonist (marketed as Ozempic, Wegovy, and Rybelsus) with robust clinical evidence for glycemic control and weight management. The molecule that mainstreamed this category and a reference point for understanding incretin-based approaches discussed in fitness communities.

Fat loss · Metabolic

A dual GIP/GLP-1 receptor agonist (marketed as Mounjaro and Zepbound) with extensive clinical data in type 2 diabetes and obesity. Frequently compared head-to-head with semaglutide in conversations about metabolic peptides and body recomposition.

Fat loss · Metabolic

A long-acting amylin-receptor analogue from Novo Nordisk, studied alone and paired with semaglutide (as "CagriSema") for weight management and type 2 diabetes. Currently one of the most-discussed "next after tirzepatide/retatrutide" names in metabolic-peptide circles.

Metabolic · Fat loss

A Boehringer Ingelheim glucagon-receptor/GLP-1-receptor dual agonist in late-stage development for obesity and MASH (fatty liver disease). Part of the current wave of multi-receptor peptides competing with tirzepatide and retatrutide for the metabolic-peptide spotlight.

Metabolic · Fat loss

A synthetic GHRH analogue with an approved indication for reducing excess abdominal fat in specific HIV-associated lipodystrophy contexts—often referenced when discussing visceral fat and GH axis research.

Fat loss · Muscle / GH axis · Metabolic

A mitochondria-derived peptide researched for metabolic regulation and exercise-related stress responses. Still early relative to incretin drugs, but frequently searched in biohacking circles.

Metabolic · Fat loss · Recovery · Longevity / aging